<i>EGLN2</i> DNA methylation and expression interact with <i>HIF1A</i> to affect survival of early-stage NSCLC

Abstract

) and significantly (P = 0.037) interacted with HIF1A expression on overall survival. Therefore, DNA methylation of EGLN2- HIF1A is a potential marker for LUAD prognosis and these genes are potential treatment targets for further development of HIF-1α inhibitors in lung cancer therapy.